View Future GrowthStandard BioTools 過去の業績過去 基準チェック /06Standard BioToolsの収益は年間平均-9.4%の割合で減少していますが、 Life Sciences業界の収益は年間 増加しています。収益は年間4.7% 1.2%割合で 減少しています。主要情報-9.36%収益成長率19.97%EPS成長率Life Sciences 業界の成長26.83%収益成長率-1.22%株主資本利益率-13.86%ネット・マージン-68.94%次回の業績アップデート05 May 2026最近の業績更新Standard BioTools Inc. to Report Q1, 2026 Results on May 05, 2026Apr 21Standard BioTools Inc. to Report Q4, 2025 Results on Feb 24, 2026Feb 10Standard BioTools Inc. to Report Q3, 2025 Results on Nov 04, 2025Oct 21Standard BioTools Inc. to Report Q2, 2025 Results on Aug 11, 2025Jul 21Standard BioTools Inc. to Report Q1, 2025 Results on May 06, 2025Apr 22Standard BioTools Inc. to Report Q4, 2024 Results on Feb 26, 2025Feb 12すべての更新を表示Recent updatesStandard BioTools Inc., Annual General Meeting, Jun 17, 2026Apr 29Standard BioTools Inc. Receives Non-Compliance Notice from Nasdaq Global Select MarketApr 26Standard BioTools Inc. to Report Q1, 2026 Results on May 05, 2026Apr 21Standard BioTools Inc. Provides Earnings Guidance for Fiscal Year 2026Feb 25Standard BioTools Inc. to Report Q4, 2025 Results on Feb 24, 2026Feb 10Illumina, Inc. (NasdaqGS:ILMN) completed the acquisition of SomaLogic, Inc., Sengenics Corporation LLC and Sengenics Corporation Pte Ltd from Standard BioTools Inc. (NasdaqGS:LAB).Jan 31Standard BioTools Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2025Jan 08Standard Biotools Inc. Affirms Earnings Guidance for the Fiscal Year 2025Nov 05Standard BioTools Inc. to Report Q3, 2025 Results on Nov 04, 2025Oct 21Standard BioTools Inc. announced delayed 10-Q filingAug 13Standard BioTools Inc. to Report Q2, 2025 Results on Aug 11, 2025Jul 21Standard BioTools Inc.(NasdaqGS:LAB) dropped from Russell 2000 Growth IndexJun 30+ 5 more updatesIllumina, Inc. (NasdaqGS:ILMN) entered into an agreement to acquire SomaLogic, Inc. from Standard BioTools Inc. (NasdaqGS:LAB) for approximately $430 million.Jun 24Standard BioTools Inc. Reaffirms Earnings Guidance for the Full Year of 2025May 07Standard BioTools Inc., Annual General Meeting, Jun 18, 2025May 01Standard BioTools Inc. Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025Apr 24Standard BioTools Inc. to Report Q1, 2025 Results on May 06, 2025Apr 22Standard Biotools Inc. Provides Earnings Guidance for the Fiscal Year 2025Feb 27Standard BioTools Inc. to Report Q4, 2024 Results on Feb 26, 2025Feb 12Standard BioTools Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2024Jan 13+ 1 more updateStandard BioTools Inc. Announces SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature MedicineJan 08Standard BioTools Inc. Announces the Appointment of Alex Kim as Chief Financial Officer, Effective November 11, 2024Nov 08+ 1 more updateStandard BioTools Inc. Reiterates Revenue Guidance for Full Year 2024Nov 02Third quarter 2024 earnings released: US$0.073 loss per share (vs US$0.27 loss in 3Q 2023) Nov 01Standard BioTools Inc. to Report Q3, 2024 Results on Oct 30, 2024Oct 16No longer forecast to breakeven Aug 02Standard BioTools Inc. Revises Revenue Guidance for the Full Year 2024Aug 02New major risk - Share price stability Aug 01Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.22 loss in 2Q 2023) Aug 01Standard BioTools Inc. Announces Chief Financial Officer ChangesAug 01High number of new and inexperienced directors Jul 25Standard BioTools Inc. to Report Q2, 2024 Results on Jul 31, 2024Jul 17Standard BioTools Inc., Annual General Meeting, Jun 27, 2024May 24Standard BioTools Inc. Reaffirms Revenue Guidance for the Fiscal Year 2024May 10Standard BioTools Inc. to Report Q1, 2024 Results on May 08, 2024Apr 27Standard BioTools Inc. Announces Operational Restructuring PlanApr 26Now 23% overvalued after recent price rise Apr 12Standard BioTools Inc. Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue ImagingApr 09Forecast to breakeven in 2026 Mar 03New major risk - Financial position Mar 01Standard BioTools Inc. Provides Revenue Guidance for the Full Year 2024Mar 01Full year 2023 earnings released: US$0.94 loss per share (vs US$2.43 loss in FY 2022) Feb 29Standard BioTools Inc. to Report Q4, 2023 Results on Feb 28, 2024Feb 15New major risk - Revenue and earnings growth Jan 09Standard Biotools Inc. Provides Revenue Guidance for the Fourth Quarter and full year 2023Jan 09SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.Jan 05+ 1 more updateThird quarter 2023 earnings released: US$265 loss per share (vs US$0.37 loss in 3Q 2022) Nov 09Standard BioTools Inc. to Report Q3, 2023 Results on Nov 07, 2023Oct 26SomaLogic, Inc. (NasdaqGM:SLGC) entered into a definitive agreement to acquire to acquire Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others for approximately $570 million in a reverse merger transaction.Oct 06Second quarter 2023 earnings released: US$0.22 loss per share (vs US$0.82 loss in 2Q 2022) Aug 09Standard BioTools Inc. to Report Q2, 2023 Results on Aug 08, 2023Jul 26High number of new directors Jun 21Senior VP & CFO recently bought €179k worth of stock May 23Standard BioTools Inc. Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics SystemMay 19Standard BioTools Inc. Appoints Jeffrey Black as Chief Financial OfficerMay 16+ 1 more updateFirst quarter 2023 earnings released: US$0.21 loss per share (vs US$0.99 loss in 1Q 2022) May 11Standard BioTools Inc. Announces Retirement of Gerhard Burbach as Member of the Board of DirectorsMay 05Standard BioTools Inc. Provides Earnings Guidance for the Year 2023Feb 16Full year 2022 earnings released: US$2.43 loss per share (vs US$0.78 loss in FY 2021) Feb 16Standard BioTools Inc. to Report Q4, 2022 Results on Feb 14, 2023Feb 01Standard Biotools Inc. Appoints Betsy Jensen as Chief Human Resources OfficerJan 04Standard BioTools Inc. (NasdaqGS:LAB) announces an Equity Buyback for $20 million worth of its shares.Nov 29Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021) Nov 10Standard BioTools Inc. to Report Q3, 2022 Results on Nov 08, 2022Oct 26Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics PlatformOct 07Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.23 loss in 2Q 2021) Aug 10Standard BioTools Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2022Aug 10Standard BioTools Inc. to Report Q2, 2022 Results on Aug 08, 2022Jul 26Standard BioTools Inc. Announces Resignation of Nicholas Khadder as Senior Vice President, General Counsel and Corporate SecretaryJul 09Standard Biotools Inc. Announces Resignation of Bradley Kreger, Senior Vice President, Global OperationsJun 29Standard BioTools Inc.(NasdaqGS:LAB) dropped from Russell Microcap Value IndexJun 26First quarter 2022 earnings released: US$0.99 loss per share (vs US$0.25 loss in 1Q 2021) May 07Standard BioTools Inc., Annual General Meeting, Jun 15, 2022May 02Standard BioTools Inc. to Report Q1, 2022 Results on May 05, 2022Apr 23Standard Biotools Inc. Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial ImagingApr 12Fluidigm Corporation Announces Board ChangesApr 06+ 2 more updatesFluidigm Corporation Announces Management ChangesMar 30Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 19Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.083 loss in 3Q 2020) Nov 09Fluidigm Corporation Announces the Publication of New Data Further Validating the Potential of Its Mass Cytometry TechnologiesSep 01Second quarter 2021 earnings released: US$0.23 loss per share (vs US$0.18 loss in 2Q 2020) Aug 08Fluidigm Corporation Revises Earnings Guidance for the Fiscal Year 2021Aug 06+ 1 more updateFluidigm Corporation Announces Launch of CyTOF XTMay 26First quarter 2021 earnings released: US$0.25 loss per share (vs US$0.23 loss in 1Q 2020) May 08Fluidigm Corporation Provides Revenue Guidance for the Second Quarter of 2021May 07+ 2 more updates収支内訳Standard BioTools の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:FLB 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 2585-591102630 Sep 25170-1481655930 Jun 25172-1381636331 Mar 25173-1461606231 Dec 2491-1371032930 Sep 2494-130972930 Jun 2498-129952731 Mar 24103-120932031 Dec 23106-75882630 Sep 23105-76865130 Jun 23105-84873431 Mar 2397-131934031 Dec 2298-1901023430 Sep 22109-179105230 Jun 22112-163107031 Mar 22124-117102031 Dec 21131-5999030 Sep 21137-68108030 Jun 21148-60106031 Mar 21143-56103031 Dec 20138-5398030 Sep 20126-4885030 Jun 20113-5583031 Mar 20115-5584031 Dec 19117-6584030 Sep 19117-6788830 Jun 19120-69871531 Mar 19118-71842331 Dec 18113-5980030 Sep 18108-55745330 Jun 18104-56744531 Mar 18102-57763831 Dec 17102-61803130 Sep 1799-6886030 Jun 1797-7287031 Mar 17101-7390031 Dec 16104-76933830 Sep 16110-7193030 Jun 16117-6191031 Mar 16117-5788031 Dec 15115-5383030 Sep 15117-5178030 Jun 15118-56790質の高い収益: FLBは現在利益が出ていません。利益率の向上: FLBは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: FLBは利益が出ておらず、過去 5 年間で損失は年間9.4%の割合で増加しています。成長の加速: FLBの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: FLBは利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( 13.9% ) と比較することは困難です。株主資本利益率高いROE: FLBは現在利益が出ていないため、自己資本利益率 ( -13.86% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/04 08:14終値2026/05/04 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Standard BioTools Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13 アナリスト機関Paul KnightBrean Capital Historical (Janney Montgomery)Sung Ji NamBTIGBryan BrokmeierCantor Fitzgerald & Co.10 その他のアナリストを表示
Illumina, Inc. (NasdaqGS:ILMN) completed the acquisition of SomaLogic, Inc., Sengenics Corporation LLC and Sengenics Corporation Pte Ltd from Standard BioTools Inc. (NasdaqGS:LAB).Jan 31
Illumina, Inc. (NasdaqGS:ILMN) entered into an agreement to acquire SomaLogic, Inc. from Standard BioTools Inc. (NasdaqGS:LAB) for approximately $430 million.Jun 24
Standard BioTools Inc. Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025Apr 24
Standard BioTools Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2024Jan 13+ 1 more update
Standard BioTools Inc. Announces SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature MedicineJan 08
Standard BioTools Inc. Announces the Appointment of Alex Kim as Chief Financial Officer, Effective November 11, 2024Nov 08+ 1 more update
Standard BioTools Inc. Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue ImagingApr 09
SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.Jan 05+ 1 more update
SomaLogic, Inc. (NasdaqGM:SLGC) entered into a definitive agreement to acquire to acquire Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others for approximately $570 million in a reverse merger transaction.Oct 06
Standard BioTools Inc. Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics SystemMay 19
Standard BioTools Inc. Announces Retirement of Gerhard Burbach as Member of the Board of DirectorsMay 05
Standard BioTools Inc. (NasdaqGS:LAB) announces an Equity Buyback for $20 million worth of its shares.Nov 29
Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics PlatformOct 07
Standard BioTools Inc. Announces Resignation of Nicholas Khadder as Senior Vice President, General Counsel and Corporate SecretaryJul 09
Standard Biotools Inc. Announces Resignation of Bradley Kreger, Senior Vice President, Global OperationsJun 29
Standard Biotools Inc. Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial ImagingApr 12
Fluidigm Corporation Announces the Publication of New Data Further Validating the Potential of Its Mass Cytometry TechnologiesSep 01